Furthermore, the combination therapy of IFN-α and sorafenib could augment the inhibition effect on the proliferation of both cell lines In conclusion, sorafenib and combination therapies are suitable for HCC cells with low or no IL-6 expression. This evidence concerns the gene IL6 and hepatocellular carcinoma.